Treatment Patterns and Outcomes of Patients Receiving Direct Oral Anticoagulants or Low Molecular Weight Heparin who Experienced Life-threatening Intracranial Hemorrhage (P5.053)

Conclusions:This study provides a real-world picture of patients receiving FXa inhibitors or LMWH, experiencing life-threatening intracranial bleeds. Despite efforts to restore hemostasis, mortality remained high and substantial healthcare resources were expended. This highlights the need to develop specific strategies for management of ICH in this patient population.Study Supported by: Portola Pharmaceuticals, Inc.Disclosure: Dr. Milling has received personal compensation for activities with CSI Behring, Janssen, BI, and Portola. Dr. Feronti has received research support from Portola. Dr. Clark has received research personal activities with Portola, Pfizer, Janssen, Cardiorentis, Ischemia Care Inc., and Radiometer. Dr. Fermann has received personal compensation for activities with Janssen and Pfizer as an advisory board member or speakers bureau member. Dr. Fermann has received research support from Novartis, Cardiorentis, Trevena, Siemens, Pfizer, Portola, Nanodetection, Radiometer, and Patient Centered Outcomes Research Institute. Dr. Song has received personal compensation for activities with Portola, Boehringer-Ingelheim, and Strykker as an advisor and/or consultant. Dr. Song has received personal compensation in an editorial capacity for AHA/ASA Stroke Journal and as an International Stroke Conference Abstract Reviewer. Dr. Song has received research support from Genentech and PRISMS. Dr. Torbati has nothing to disclose. Dr. Weiss has received personal compensation for ...

Source: Neurology - April 17, 2017 Category: Neurology Authors: Milling, T. J., Feronti, C., Clark, C. L., Fermann, G. J., Song, S. S., Torbati, S. S., Weiss, J., Patel, D., Neuman, W. R. Tags: Neurocritical Care: Intracerebral Hemorrhage Source Type: research